EvoNext Holdings (XSWX:EVE) Research & Development: CHF0.00 Mil (TTM As of Dec. 2025)


XSWX:EVE EvoNext Holdings SA XSWX:EVE
30 GF Score
Price CHF1.79
GF Value CHF0.95
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is EvoNext Holdings Research & Development?

EvoNext Holdings XSWX:EVE +2.87% 30 Research & Development is CHF0.00 Mil as of Dec. 2025. GuruFocus rates XSWX:EVE with a GF Score™ of 30/100 and a GF Value™ of CHF0.95 (Significantly Overvalued). The stock has 3 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. EvoNext Holdings's Research & Development for the six months ended in Dec. 2025 was CHF0.00 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 was CHF0.00 Mil.

EvoNext Holdings  (XSWX:EVE) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

EvoNext Holdings Research & Development Related Terms

EvoNext Holdings Research & Development Historical Data

* Premium members only.

The historical data trend for EvoNext Holdings's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

EvoNext Holdings Research & Development Chart

EvoNext Holdings Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 22.44 23.60 32.12 0.00 0.00

EvoNext Holdings Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.22 0.00 0.00 0.00 0.00
XSWX:EVE
30GF Score
EvoNext Holdings SA XSWX:EVE
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

EvoNext Holdings Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was CHF0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of CHF0.00 Mil mean?
EvoNext Holdings (XSWX:EVE) has a Research & Development of CHF0.00 Mil as of Dec. 2025. Research and development expense is the total cost for research and development activities. View historical data on EvoNext Holdings and its competitors.
Is EvoNext Holdings' Research & Development too high?
EvoNext Holdings' current Research & Development is CHF0.00 Mil. Overall, EvoNext Holdings has a GF Score™ of 30/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does EvoNext Holdings' Research & Development compare to XXI and DMII?
EvoNext Holdings' Research & Development of CHF0.00 Mil can be compared against companies in the Diversified Financial Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Diversified Financial Services company?
A good Research & Development depends on the Diversified Financial Services industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on EvoNext Holdings and its competitors. EvoNext Holdings's current Research & Development is CHF0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is EvoNext Holdings stock overvalued right now?
Based on GuruFocus' analysis, EvoNext Holdings (XSWX:EVE) is currently considered Significantly Overvalued. The stock's GF Value™ is CHF0.95, compared to a current price of CHF1.79 — trading 88.4% above its estimated fair value. The current Research & Development is CHF0.00 Mil. EvoNext Holdings' overall GF Score™ is 30/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For EvoNext Holdings (XSWX:EVE), the current Research & Development is CHF0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is EvoNext Holdings (XSWX:EVE) Overvalued in 2026?

Based on GuruFocus' analysis, EvoNext Holdings stock appears to be overvalued. The current stock price of CHF1.79 is trading 88.4% above its estimated GF Value™ of CHF0.95. GuruFocus considers EvoNext Holdings to be Significantly Overvalued.

Key valuation signals for XSWX:EVE:

  • Research & Development: CHF0.00 Mil
  • GF Value™: CHF0.95 vs. price of CHF1.79 (88.4% above fair value)
  • GF Score™: 30/100 with 3 warning signs

No single metric tells the full story. See the XSWX:EVE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

EvoNext Holdings Business Description

Address Angensteinerstrasse 6, Reinach, CHE, CH-4153
EvoNext Holdings SA has no operating business.
30GF Score

Get the complete analysis for XSWX:EVE

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF1.79
Price
CHF0.95
GF Value